{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T03:26:59Z","timestamp":1793330819078,"version":"4.5.0"},"reference-count":19,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T00:00:00Z","timestamp":1610409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Drug-drug interactions (DDIs) with oral antineoplastics (OAs) are of increasing concern given the rapid increase in OA approvals and use in cancer patients. A small pilot study of 20 DDIs with OAs showed significant variability in commonly used DDI screening databases in sensitivity of detecting potentially clinically relevant DDIs. This study builds upon that work by expanding the number of potential DDIs analyzed and including a specificity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Newly approved OAs from 2016 to May 2019 (n\u2009=\u200922) were included in this analysis. Prescribing information for each drug was reviewed. A list of explicit and theoretical drug interactions was created for each OA by the two investigators. A board-certified oncology pharmacist adjudicated all DDI pairs for potential clinical significance. In total, 229 DDI pairs were used to analyze sensitivity of 5 DDI databases (Lexicomp\u00ae, Micromedex\u00ae, Medscape, Eporactes\u00ae, &amp; Drugs.com). Additionally, 64 \u201cdummy\u201d or false DDI pairs were created to analyze specificity. Sensitivity and specific were analyzed using Cochran\u2019s Qtest, while accuracy was analyzed using chi-square test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was significant variability among the databases with regards to sensitivity (p\u2009&lt;\u20090.0001), specificity (p\u2009&lt;\u20090.0001), and accuracy (p\u2009&lt;\u20090.0001). In terms of accuracy (max score\u2009=\u2009400), Lexicomp\u00ae(355), Epocrates\u00ae (344), and Drugs.com (352) scored higher than MicroMedex\u00ae (270) and Medscape (280).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Considerable variability exists among DDI screening databases with regards to OAs and potential drug interactions. Clinicians should be vigilant in both screening for DDIs with OAs and describing DDIs encountered in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220984244","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T21:29:09Z","timestamp":1610659749000},"page":"82-86","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":25,"title":["Sensitivity and specificity of drug interaction databases to detect interactions with recently approved oral antineoplastics"],"prefix":"10.1177","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6096-9687","authenticated-orcid":false,"given":"John B","family":"Bossaer","sequence":"first","affiliation":[{"name":"Gatton College of Pharmacy, Johnson City, TN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Eskens","sequence":"additional","affiliation":[{"name":"University of Louisville, Louisville, KY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin","family":"Gardner","sequence":"additional","affiliation":[{"name":"University of North Carolina System, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2021,1,12]]},"reference":[{"key":"bibr1-1078155220984244","unstructured":"Center for Drug Evaluation and Research: New Drugs at FDA, www.fda.gov\/drugs\/development-approval-process-drugs\/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products (accessed 4 May 2020)."},{"key":"bibr2-1078155220984244","unstructured":"Streicher C, Daulange A, Madranges N, et\u00a0al. Severe rhabdomyolysis induced by possible drug-drug interaction between ribociclib and simvastatin.\n                      J Oncol Pharm Practice\n                      . Epub ahead of print 29 July 2020. DOI: 10.1177%2F1078155220945365"},{"key":"bibr3-1078155220984244","volume-title":"Package insert","author":"Kisqali","year":"2020"},{"key":"bibr4-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2017.01.003"},{"key":"bibr5-1078155220984244","first-page":"1719","volume":"24","author":"Ergun Y","year":"2019","journal-title":"J Buon"},{"key":"bibr6-1078155220984244","first-page":"10","volume":"42","author":"Diaz-Carrasco MS","year":"2018","journal-title":"Farm Hosp"},{"key":"bibr7-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216664200"},{"key":"bibr8-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.020859"},{"key":"bibr9-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv029"},{"key":"bibr10-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5076-0"},{"key":"bibr11-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1177\/1078155216682311"},{"key":"bibr12-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2016.016212"},{"key":"bibr13-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-008-9191-x"},{"key":"bibr14-1078155220984244","doi-asserted-by":"publisher","DOI":"10.4103\/2279-042X.192461"},{"key":"bibr15-1078155220984244","unstructured":"Cometriq [package insert]. Alameda, CA: Exelixis, Inc, www.cometriq.com\/downloads\/Cometriq_Full_Prescribing_Information.pdf (2020, accessed 8 June 2020)."},{"key":"bibr16-1078155220984244","unstructured":"Cabometyx [package insert]. Alameda, CA: Exelixis, Inc, www.cabometyxhcp.com\/pi\/ (2020, accessed 8 June 2020)."},{"key":"bibr17-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3349-y"},{"key":"bibr18-1078155220984244","unstructured":"Tabrecta [package insert]. East Hanover, NJ; Novartis Pharmaceuticals Corp, www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/213591s000lbl.pdf (2019, accessed 19 October 2020)."},{"key":"bibr19-1078155220984244","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0706-9"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220984244","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220984244","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220984244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:24:27Z","timestamp":1777688667000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220984244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,12]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.1177\/1078155220984244"],"URL":"https:\/\/doi.org\/10.1177\/1078155220984244","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,12]]}}}